Memorial Sloan Kettering pancreas cancer program
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer
This program uses advanced genetic testing and new treatment approaches to try to improve care for people with locally advanced or metastatic pancreas cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11169807 on NIH RePORTER |
What this research studies
If you join, doctors will collect tumor and blood samples and use next-generation molecular tests to look for genetic changes that might explain why some people respond especially well to treatments. The team combines laboratory analysis with clinical care, offering access to cytotoxic, targeted, and immune-based treatment options or trials guided by molecular findings. The focus is on patients with stage III or IV pancreatic ductal adenocarcinoma, and clinicians aim to match therapies to each patient’s tumor profile. The work links lab discoveries to real-world treatment choices to help guide better care.
Who could benefit from this research
Good fit: Ideal candidates are adults with locally advanced (stage III) or metastatic (stage IV) pancreatic ductal adenocarcinoma who can provide tissue and blood samples and are willing to consider molecularly guided treatments or clinical trials.
Not a fit: People with very early-stage pancreas cancer, those who cannot provide tissue or blood samples, or those unable to travel to MSK may not receive direct benefit from this program.
Why it matters
Potential benefit: If successful, this program could help match patients to more effective therapies based on their tumor’s genetics and improve survival for people with advanced pancreas cancer.
How similar studies have performed: Some prior work has shown that a subset of pancreatic cancer patients can have exceptional responses linked to molecular features, but integrating next-generation profiling with new targeted and immune therapies is still an evolving approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: O'reilly, Eileen Mary — Sloan-Kettering Inst Can Research
- Study coordinator: O'reilly, Eileen Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.